探讨父母的观点：母亲 RSV 疫苗接种与婴儿 RSV 单克隆抗体。
Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody.
机构信息
Department of Paediatric Infectious Diseases, Children's Health Ireland at Crumlin and Temple Street, Dublin, Ireland.
School of Medicine, University College Dublin, Dublin, Ireland.
出版信息
Hum Vaccin Immunother. 2024 Dec 31;20(1):2341505. doi: 10.1080/21645515.2024.2341505. Epub 2024 May 9.
Abstract
Respiratory Syncytial Virus poses a significant global public health threat, particularly affecting infants aged less than one year of age. Recently, two forms of passive immunization against infant RSV have been developed and brought to market; nirsevimab a long-acting monoclonal antibody (mAb) and RSV-PreF, a maternal RSV vaccine. The acceptability and uptake of these products will play a pivotal role in determining the success of any national immunization strategy aimed at safeguarding infants from RSV. It is crucial at this time to reflect on the factors that influence parental decisions surrounding immunization to facilitate more informed discussions, enhance healthcare communication, and contribute to the design of effective RSV prevention strategies that resonate with the concerns and aspirations of parents worldwide.
摘要
呼吸道合胞病毒对全球公共卫生构成重大威胁，尤其对年龄不足 1 岁的婴儿影响较大。最近，已开发出两种针对婴儿呼吸道合胞病毒的被动免疫制剂并推向市场，即长效单克隆抗体 nirsevimab 和 RSV-PreF（一种母亲呼吸道合胞病毒疫苗）。这些产品的可接受性和使用率将在很大程度上决定任何旨在保护婴儿免受呼吸道合胞病毒侵害的国家免疫策略的成功与否。目前，我们需要反思影响父母免疫决策的因素，以便更有针对性地开展讨论，加强医疗保健沟通，并有助于制定有效的呼吸道合胞病毒预防策略，以满足全球父母的关切和期望。
相似文献
1
Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2341505. doi: 10.1080/21645515.2024.2341505. Epub 2024 May 9.
2
Respiratory Syncytial Virus Vaccine and Nirsevimab Uptake Among Pregnant People and Their Neonates.
JAMA Netw Open. 2025 Feb 3;8(2):e2460735. doi: 10.1001/jamanetworkopen.2024.60735.
3
Provider Guidance for the Prevention of Respiratory Syncytial Virus in Infants: Maternal Vaccination Versus Infant Monoclonal Antibody Treatment.
Obstet Gynecol Surv. 2024 Oct;79(10):585-590. doi: 10.1097/OGX.0000000000001324.
4
Impact of routine prophylaxis with monoclonal antibodies and maternal immunisation to prevent respiratory syncytial virus hospitalisations, Lombardy region, Italy, 2024/25 season.
Euro Surveill. 2025 Apr;30(14). doi: 10.2807/1560-7917.ES.2025.30.14.2400637.
5
Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged <8 Months - United States, April 2024.
MMWR Morb Mortal Wkly Rep. 2024 Sep 26;73(38):837-843. doi: 10.15585/mmwr.mm7338a2.
6
Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial.
Vaccine. 2024 Sep 17;42(22):126041. doi: 10.1016/j.vaccine.2024.06.009. Epub 2024 Jun 8.
7
Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada.
Vaccine. 2025 Mar 19;50:126818. doi: 10.1016/j.vaccine.2025.126818. Epub 2025 Feb 6.
8
Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants.
Vaccine. 2024 Aug 30;42(21):126164. doi: 10.1016/j.vaccine.2024.126164. Epub 2024 Jul 30.
9
Respiratory syncytial virus (RSV) prevention: Perception and willingness of expectant parents in the Netherlands.
Vaccine. 2025 Jan 12;44:126541. doi: 10.1016/j.vaccine.2024.126541. Epub 2024 Nov 30.
10
Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial.
Obstet Gynecol. 2025 Feb 1;145(2):157-167. doi: 10.1097/AOG.0000000000005816. Epub 2025 Jan 2.
引用本文的文献
1
Epidemiologic characteristics of immunoglobulin M antibodies in lower respiratory tract infection pathogens of children: association with severe pneumonia in Chengdu city from 2019 to 2023.
Am J Transl Res. 2025 Jul 15;17(7):5271-5283. doi: 10.62347/BBXL3592. eCollection 2025.
2
Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA (Advancing RSV Management And Disease Awareness) Taskforce.
Open Forum Infect Dis. 2025 Jul 2;12(7):ofaf396. doi: 10.1093/ofid/ofaf396. eCollection 2025 Jul.
3
Correlation analysis between the severity of respiratory syncytial virus pneumonia and the expression levels of inflammatory cytokines in bronchoalveolar lavage fluid among infants and young children.
Front Pediatr. 2025 Feb 19;13:1482029. doi: 10.3389/fped.2025.1482029. eCollection 2025.
4
Nirsevimab Prophylaxis for Reduction of Respiratory Syncytial Virus Complications in Hospitalised Infants: The Multi-Centre Study During the 2023-2024 Season in Andalusia, Spain (NIRSEGRAND).
Vaccines (Basel). 2025 Feb 12;13(2):175. doi: 10.3390/vaccines13020175.
5
Knowledge and Attitudes Regarding Respiratory Syncytial Virus (RSV) Prevention: A Systematic Review.
Vaccines (Basel). 2025 Feb 6;13(2):159. doi: 10.3390/vaccines13020159.
6
Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in France.
EClinicalMedicine. 2024 Dec 9;79:102986. doi: 10.1016/j.eclinm.2024.102986. eCollection 2025 Jan.
本文引用的文献
1
Maternal awareness, acceptability and willingness towards respiratory syncytial virus (RSV) vaccination during pregnancy in Ireland.
Immun Inflamm Dis. 2024 Apr;12(4):e1257. doi: 10.1002/iid3.1257.
2
RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes.
N Engl J Med. 2024 Mar 14;390(11):1009-1021. doi: 10.1056/NEJMoa2305478.
3
Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.
N Engl J Med. 2023 Dec 28;389(26):2425-2435. doi: 10.1056/NEJMoa2309189.
4
Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP).
An Pediatr (Engl Ed). 2023 Oct;99(4):257-263. doi: 10.1016/j.anpede.2023.09.006. Epub 2023 Sep 22.
5
Summer 2023 ACIP Update: RSV Prevention and Updated Recommendations on Other Vaccines.
Pediatrics. 2023 Nov 1;152(5). doi: 10.1542/peds.2023-063955.
6
Infants Admitted to US Intensive Care Units for RSV Infection During the 2022 Seasonal Peak.
JAMA Netw Open. 2023 Aug 1;6(8):e2328950. doi: 10.1001/jamanetworkopen.2023.28950.
7
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.
N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5.
8
First hepatitis B vaccine uptake in neonates prior to and during the COVID-19 pandemic.
Vaccine. 2023 Apr 24;41(17):2824-2828. doi: 10.1016/j.vaccine.2023.03.039. Epub 2023 Mar 27.
9
Maternity care provider acceptance of a future Group B Streptococcus vaccine - A qualitative study in three countries.
Vaccine. 2023 Mar 17;41(12):2013-2021. doi: 10.1016/j.vaccine.2023.02.037. Epub 2023 Feb 18.
10
Monitoring the vaccination of pregnant women against pertussis - single-centre one-year study in the Czech Republic.
Bratisl Lek Listy. 2023;124(4):285-291. doi: 10.4149/BLL_2023_044.
Zotero 插件